ISRCTN21353122
Completed
未知
Prevention of psychosis with a cognitive behavioural intervention in help-seeking young people with an at risk mental state for developing psychosis
The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)0 sites240 target enrollmentJuly 11, 2008
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)
- Enrollment
- 240
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged 14 to 35 years, either sex
- •2\. Fullfilling At Risk Mental State criteria of the Comprehensive Assessment of At Risk Mental State, criteria of July 2007
Exclusion Criteria
- •1\. Current or previous receipt of antipsychotic medication
- •2\. Moderate to severe learning disability
- •3\. Organic impairment
- •4\. Non\-Dutch speaking
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prevention of psychosis with a cognitive behavioural intervention in help-seeking young people with an at risk mental state for developing psychosisNL-OMON31359Parnassia (Den Haag)240
Recruiting
Not Applicable
Prevention of psychosis with a cognitive behavioural intervention in help-seeking young people with an at risk mental state for developing psychosis.1. At risk mental state<br />2. psychosis<br />3. prevention<br />4. ultrahoog risico<br />5. psychose<br />6. preventie.NL-OMON23126Vrije Universiteit, Vakgroep Klinische Psychologie.240
Completed
Not Applicable
Primary prevention of psychosis through interventions in the prodromal phaseISRCTN20328848Stavanger University Hospital (Norway)240
Completed
Phase 4
Second generation intervention research in the pre-psychotic phase of illness in schizophrenia and related psychosesSchizophrenia and other psychotic disordersMental Health - SchizophreniaMental Health - Other mental health disordersACTRN12605000247673Janssen-Cilag Pharmaceuticals119
Active, not recruiting
Phase 1
Hydrocortisone as co-treatment to prevent neuropsychiatric adverse effects of dexamethasone.europsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance.Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2017-003705-17-NLMC180